Free tool
FAERS Monitor: Macrobid
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020064 or its brand name (Macrobid, Nitrofurantoin, Nitrofurantoin, Macrocrystalline). Reports on generic versions are filed under their own applications.
Reports
5,883
Serious
4,020
68% of reports
Hospitalization
1,958
Death reported
335
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- urinary tract infection820
- headache623
- nausea590
- drug hypersensitivity552
- fatigue537
- pain505
- dyspnoea444
- drug ineffective438
- off label use398
- diarrhoea373
- dizziness370
- vomiting347
- asthenia318
- pyrexia304
- fall300
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 85 |
| 2005 | 83 |
| 2006 | 103 |
| 2007 | 80 |
| 2008 | 99 |
| 2009 | 126 |
| 2010 | 177 |
| 2011 | 249 |
| 2012 | 274 |
| 2013 | 227 |
| 2014 | 329 |
| 2015 | 385 |
| 2016 | 500 |
| 2017 | 406 |
| 2018 | 400 |
| 2019 | 432 |
| 2020 | 469 |
| 2021 | 294 |
| 2022 | 255 |
| 2023 | 249 |
| 2024 | 229 |
| 2025 | 261 |
| 2026 | 171 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,048,276 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| urinary tract infectionSignal | 820 | 17.3 | 16.2 | 12,590 |
| drug hypersensitivitySignal | 552 | 10.2 | 9.4 | 4,614 |
| headacheSignal | 623 | 3.6 | 3.3 | 1,175 |
| fallSignal | 300 | 3.2 | 2.9 | 465 |
| pyrexiaSignal | 304 | 3.1 | 2.8 | 449 |
| astheniaSignal | 318 | 3.0 | 2.7 | 437 |
| painSignal | 505 | 2.9 | 2.7 | 664 |
| dyspnoeaSignal | 444 | 2.8 | 2.6 | 528 |
| nauseaSignal | 590 | 2.7 | 2.5 | 636 |
| dizzinessSignal | 370 | 2.7 | 2.4 | 388 |
| vomitingSignal | 347 | 2.6 | 2.4 | 360 |
| fatigueSignal | 537 | 2.5 | 2.3 | 485 |
| diarrhoeaSignal | 373 | 2.1 | 1.9 | 211 |
| off label use | 398 | 1.6 | 1.5 | 99 |
| drug ineffective | 438 | 1.2 | 1.1 | 14 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.